The literature contains a substantial amount of information about factors that adversely influence the linear growth in up to 85% of patients undergoing haematopoietic SCT (HSCT) with TBI and/or cranial irradiation (CI) for acute leukaemia (AL). By contrast, only a few studies have evaluated the impact of growth hormone (GH) therapy on growth rate and final height (FH) in these children. We evaluated growth rates during the preand post-transplant periods to FH in a group of 25 children treated with HSCT (n ¼ 22), TBI (n ¼ 21) or/and CI (n ¼ 8) for AL and receiving GH therapy. At the start of GH treatment, the median height Z-score was À2.19 (À3.95 to 0.02), significantly lower than at AL diagnosis (Po0.001). Overall height gain from start of GH treatment to FH was 0.59Z (À2.72 to 2.93) with a median height Z-score at FH of À1.35 (À5.35 to 0.27). This overall height gain effect was greater in girls than in boys (P ¼ 0.04). The number of children with heights in the reference population range was greater after than before GH therapy (P ¼ 0.07). At FH the GVHD and GH treatments lasting o2 years were associated with shorter FH (P ¼ 0.02 and 0.05). We found a measurable beneficial effect of GH treatment on growth up to FH.
Introduction
The growth and growth hormone (GH) deficiency have been observed in children after haematopoietic SCT (HSCT) with TBI [1] [2] [3] [4] [5] and those previously undergoing central nervous system irradiation (CI) to treat acute leukaemia (AL). [1] [2] [3] [5] [6] [7] Conditioning regimen chemotherapy and irradiation are often superimposed on the 'standard' therapies, which may compromise pubertal development and final height (FH) in their own right. 8 Also, with the increasing number of survivors and duration of follow-up, patients may experience a significant loss of height potential. The literature contains a number of studies about factors that adversely affect growth in children treated for AL (age at the time of AL treatment, irradiation dose and fraction size, and so on). 3, 6, [9] [10] [11] [12] [13] [14] By contrast, only a few studies have evaluated the impact of GH replacement therapy on growth rate and FH in these children. 1, 2, 7, [15] [16] [17] A better understanding of the factors influencing response to GH will allow the identification of patients who can benefit from appropriate hormonal replacement therapy. This is important given that currently fewer than half of the GH deficiency (GHD) children after HSCT or CI receive GH therapy. 6, 18 We evaluated growth rates during the pre-and posttransplant periods to FH in a group of 25 children treated with HSCT, TBI or/and CI for AL and subsequently receiving supplemental GH therapy. The impact of GH treatment on FH was of particular interest.
Patients and methods

Study design
This study was based on an analysis of growth, pubertal development and hormonal status data collected prospectively as part of an ongoing French long-term follow-up programme for patients treated for AL in childhood. Details of the whole programme, known as 'LEA' (for 'Leuce´mie de l'Enfant et de l'Adolescent') have already been described elsewhere. 19 Briefly, this programme was initiated in 2003 to make a prospective evaluation of the long-term health status, quality of life and socioeconomic status of childhood leukaemia survivors enrolled in treatment from 1980 to the present in the participating centres. At the end of 2009, the cohort comprised 944 patients. In application of French law, this long-term follow-up programme was filed with the Comite´consultatif sur le traitement de l'information en matie`re de recherche dans le domaine de la sante´(French data privacy authority governing healthcare research) and approved by the CNIL (French national data privacy authority). Written informed consent was obtained from the patients and their parents or legal guardians for programme participation. In the entire cohort of 944 patients there were 257 patients who had had HSCT. Among these 188 had had TBI (14 had also had previous CI) and 12 had had only CI. Among no transplanted patients 121 had had CI. It makes a total of 321 irradiated patients. In the entire cohort of 944 patients there were 54 patients with identified GHD. A total of 35 patients were treated with GH and 25 had achieved FH at the time of their last visit. This study was restricted to those patients who met all the following inclusion criteria: (1) had undergone HSCT, including TBI or/and cranial irradiation (CI), (2) had GHD and had received supplemental GH therapy and (3) had achieved FH at the time of their last visit. Of the 944 children included in the LEA programme 25 met study entry criteria and are described here.
Patients
Twenty-five children with AL (21 lymphoblastic and 4 myeloid) diagnosed at a median age of 4.4 years (range 1.9-12.3) underwent treatment according to the French multicenter protocols applicable at the time of diagnosis (from June 1980 to March 2001). In addition to multiagent chemotherapy, eight children had received CI at target doses ranging from 18 to 24 Gy (including the spine in seven patients). In six children the CI was given as 'prophylaxis' in the first 6 months of treatment (in four of them it was years before HSCT/TBI administration). In two children CI was given as treatment for a CNS relapse 4 and 6 years, respectively, after AL diagnosis (in one of them CI was given shortly before HSCT/TBI). Three children were given CI only without HSCT/TBI (Table 1) .
Twenty-two children had received HSCT at a median age of 6.7 years (range 2.4-12.7). Seventeen patients underwent HSCT/TBI before and 5 after the age of 10 years. Seven patients underwent HSCT/TBI in first and 15 in second or subsequent CR. The median times from AL diagnosis to HSCT/TBI were 0.38 years (range 0.31-0.42) for patients in first CR and 2.17 years (range 0.96-4.46) for those in second or subsequent CR. HSCT preparative regimens depended on diagnosis, protocols in use at the time of transplantation, phase of patient disease and donor type. Patients were conditioned with CY (n ¼ 3), melphalan þ /À cytarabine (n ¼ 18) plus TBI (n ¼ 21). 20 TBI was given as 2-Gy doses twice a day for a total of six doses (n ¼ 17), five doses (n ¼ 2) or seven doses (n ¼ 1). One patient received a total of 6 Gy in six fractions. One patient (number 21) received misulban/melphalan conditioning regimen without TBI. Two boys (Nos 2 and 10) received, respectively, 16 and 24 Gy testicular irradiation as treatment for testicular leukaemia and five others (Nos 1, 3, 7, 12 and 16) 4-6 Gy testicular boost irradiation at the time of TBI. Eight children were treated with autologous and 14 with allogeneic HSCT. Thirteen patients developed GVHD graded as described previously. 21 Acute GVHD grade II or more occurred in two children and extensive chronic GVHD in three children. All of them were given steroid therapy. Median patient age at the last time point was 22.5 years (range 18.5-36.0).
Methods
Height evaluation. Height was measured before and during AL treatment and at least annually thereafter until 18 years of age or more. Height was measured using a Harpenden stadiometer (Holtain Ltd, Crymych, UK) and was expressed as height-for-age-and-sex Z-score, calculated as height minus mean height for age and sex divided by the s.d. of height for age and sex. This Z-score value allows data from boys and girls to be compared without distinction. Height-for-age-and-sex Z-scores were calculated using the French sequential study of growth. These values were compared with the healthy reference population used in the French growth charts, which have normal reference values for stature by age and sex for children aged 0-18 years. 22 A normal range is from À2.00Z to 2.00Z, a negative value indicates below-age-expected height, and a positive value indicates above-age-expected height.
Height-for-age-and-sex Z-scores were calculated at four key time points: AL diagnosis (Z 1 ), first irradiation (HSCT/ TBI or CI, whichever came first; Z 2 ), start of GH treatment (Z 4 ) and FH (Z 6 ). The intermediate time points representing the HSCT/TBI (Z 2a ), CI (Z 2b ), GHD diagnosis (Z 3 ) and end of GH treatment (Z 5 ) were also analysed. Height at each time point was defined by its associated height-forage-and-sex Z-score. Changes in height-for-age-and-sex Z-scores between key time points were also calculated (DZ). FH was defined as the tallest height measured at patient age 18 years or older, and when height velocity was o1 cm/ year. For three patients who were older than 18 years when they started their annual follow-up in the LEA longterm follow-up programme and for whom we did not have the 18th birthday height but only programme inclusion height we arbitrarily took their 20th birthday as the time of FH.
GH testing. In LEA programme, all children with a fall in growth velocity were screened for GHD. All patients are given an annual evaluation of basal plasma insulin-like growth factor-I concentration. GH secretion in response to The cutoff level for diagnosis of GHD was considered to correspond to a peak level after stimulation o20 mUI/L (10 ng/mL). The tests were performed at least 6 months away from any antileukaemic treatment.
All patients were also tested for thyroid function. Luteinizing hormone, follicle-stimulating hormone and either estradiol or testosterone were assayed.
GH supplemental therapy. All the patients received GH treatment with recombinant human GH at 0.4-0.7 IU/kg/ week, administered as s.c. injection 4-7 days every week, corresponding to 0.033 mg/kg body wt/day (0.1 IU/kg body wt/day).
Statistical analysis. All data are reported as medians (range). The characteristics of patients by age, sex, diagnosis, transplant and irradiation type were compared in univariate analysis using the Kruskal-Wallis test for continuous variables and Fisher's exact test for categorical factors. Growth in these patients was quantified by plotting the median height Z-scores at each key time point. Height Z-scores were compared across patient subgroups using two-way repeated measures analysis of variance (and the Friedman test when appropriate) followed by a TukeyKrammer test to compare differences between and within groups. This analysis was completed with linear mixed models (multivariate analysis) to assess the impact of AL treatment and GH therapy on growth over time. Change in height Z-score from AL to GHD diagnosis and from GH treatment start to FH was evaluated. Factors considered as possibly contributing to this change in height Z-score were also examined. These factors included age at different time points, sex, primary diagnosis, exposure to CI and/or HSCT, type of HSCT, GVHD and duration of GH treatment. The effect of GH therapy on growth was then tested, after adjusting for patient characteristics. Interactive effects with GH therapy were also investigated. Linear mixed models allow the comparison of change in height Z-scores between covariate groups over time. The parameters in this regression model were estimated by the method of maximum likelihood and the Wald statistic was used to test the equality of growth rates. The statistical analyses were performed using the STATA statistical software, version 10.0 (StataCorp, College Station, TX, USA); Po0.05 was considered statistically significant. Figure 1 shows the median height Z-scores over time for all the patients. At the time of AL diagnosis (Z 1 ), heights were normal in 24 of the 25 patients (96%) and one patient was taller than the normal reference population. The patients older than 5 years at diagnosis were significantly shorter than those who were younger than 5 (median Z-score À0.44 vs 0.62, respectively; P ¼ 0.01).
Results
Growth before GH therapy
When the AL treatment started (Z 1 ) height Z-scores started to decrease. At the time of first irradiation (Z 2 ) median Z-score was À0.36 (range À1.88 to 3.22, not significantly different from Z 1 , P ¼ 0.34). However, at the time of GHD diagnosis (Z 3 ) it was À2.12 (range À3.98 to 0.5, significantly lower than Z 1 , Po0.001).
Median loss in height Z-score between AL diagnosis and first irradiation (DZ 2 ÀZ 1 ) was À0.25 (range À1.59 to 1.75). In those patients who were irradiated in first CR, median height was nearly the same at first irradiation (HSCT/TBI or CI) as at AL diagnosis (n ¼ 13, median DZ 2 ÀZ 1 ¼ À0.28). However, it was clearly decreased in those irradiated in second or subsequent CR (n ¼ 12, median DZ 2 ÀZ 1 ¼ À0.45). At the time of first irradiation normal height was still seen in 23/25 children (92%), and the two remaining patients were still taller than the normal reference population.
Median loss in height Z-score between HSCT/TBI or CI and GHD diagnosis (DZ 3 ÀZ 2 ) was À1.73 (range À5.63 to À0.25) and was significantly more marked than the loss observed from AL diagnosis to first irradiation (DZ 2 ÀZ 1 ). However, considering median Z-score decrease rate (Z loss per year) there was no difference before (À0.38 Z/year, range À3.41 to 1.78) or after (À0.39 Z/year, range À1.01 to À0.07) the first irradiation (HSCT/TBI or CI; P ¼ 0.44). Hence, the overall growth rate decrease from AL diagnosis to GH treatment start was À0.38 Z/year (range À0.89 to À0.08). At the time of GHD diagnosis only 12/25 (48%) patients had normal heights and none was taller than the normal reference population.
In univariate analysis, height loss from AL diagnosis to GHD diagnosis (DZ 3 ÀZ 1 ) was greater in the girls (P ¼ 0.007; Figure 2 ) and in patients younger than 5 years at the time of CI (P ¼ 0.02). There was no significant correlation between HSCT/TBI, GVHD and height loss from AL diagnosis to GHD diagnosis (DZ 3 ÀZ 1 ).
Growth during and after GH therapy
Patients were diagnosed with GHD at a median of 12.4 years (range 6.8-15.6) and 6.2 years (range 2.1-11.7) after AL diagnosis and 4.6 years (range 1.7-11.6) after first irradiation (HSCT/TBI or CI). The median time from GHD diagnosis to start of GH therapy was 0.6 years (range 0.2-3.4 years).
At the time patients started GH treatment, chronological age was 13.2 years (range 7.3-16.2 years) and bone age, available in 20 of the 25 patients (80%), was 11 years (range 7.0-14.5 years). Bone age was within 2 years of chronological age for 12 patients and was 42 years lower for age in 8 patients. Median Z-score (Z 4 ) was À2.19 (range À3.95 to 0.02), significantly oZ 1 (Po0.001). Fourteen children (56%) had heights 42Z below the mean at GH treatment start. The patients older than 10 years at the time of GH treatment start were shorter than those younger than 10 (P ¼ 0.01).
GH treatment lasted for a median 3.7 years (range 1.0-8.9). Median Z-score recovery during GH treatment (DZ 5 ÀZ 4 ) was 0.43 (range À1.10 to 2.91) and the median recovery rate was 0.12 Z/year (range À1.31 to 0.78). In 17 children height Z-scores increased whereas in 8 children it continued to decrease after the start of GH treatment. Similar proportions of patients in the 'responding' group and in the 'nonresponding' group received CI, allo-HSCT and had steroid therapy as treatment for GVHD.
After discontinuation of GH treatment Z-score increase was observed in 18 children (catch-up continued in 14 and started in the other 4). Median recovery rate was not significantly slower after GH treatment discontinuation: 0.03 Z/year (range À0.29 to 0.41) than 'on GH treatment' (P ¼ 0.17). Overall recovery from start of GH treatment to FH (DZ 6 ÀZ 4 ) was 0.59Z (range À2.72 to 2.93). This overall recovery effect (DZ 6 ÀZ 4 ) was stronger in girls (P ¼ 0.04; Figure 2 ).
Patients who received allo-HSCT/TBI and patients who had GVHD tended to have lower height Z-scores at the time of GH deficit diagnosis (Z 3 ). This pattern persisted in time, and the difference became statistically significant from the start of GH treatment (Z 4 ) until FH (Z 6 ; P ¼ 0.05 for HSCT/TBI and 0.03 for GVHD; Figure 2 ).
FH
The median cumulative change in height Z-score from AL diagnosis to FH was À1.94. (range À4.58 to 0.40) with median Z-score at FH of À1.35 (range À5.35 to 0.27). After GH supplemental treatment FH were in the reference population range in 19 of the 25 patients (76%), whereas six children had a FH that remained below the À2Z-score. However, the proportion of children with heights in the reference population range was greater after than before GH therapy (19/25 vs 11/25, P ¼ 0.07).
At FH, the GVHD and GH treatment lasting o2 years were significantly associated with a shorter FH in univariate analysis (P ¼ 0.02 and 0.05, respectively). In the multivariate analysis, there was no covariate significantly associated with a lower FH.
Toxicity after GH therapy
None of the GH-treated patients developed any adverse effects requiring discontinuation of GH. None had a relapse. In all, 8 secondary neoplasms occurred in seven patients during GH treatment (two patients) or after GH treatment had been discontinued (five patients) for 4-16 years. Among these seven patients, three developed papillary thyroid carcinoma, one papillary thyroid carcinoma and malignant peripheral nerve sheath tumour, one renal carcinoma, one melanoma and one basal cell epithelioma. In two patients who had thyroid carcinoma while on GH treatment the treatment was not stopped. Other complications or late effects observed after GH treatment were exostosis in one patient and benign schwannoma in one patient (Table 2 ). Six key time points: see Figure 1 . Height loss from AL diagnosis to GHD diagnosis (DZ 3 ÀZ 1 ) was greater (P ¼ 0.007) and treatment effect (DZ 6 ÀZ 4 ) was stronger in girls (P ¼ 0.04). Height Z-scores were significantly lowers from points Z 4 to FH in patients with GVHD (P ¼ 0.034).
Discussion
Although the majority of studies on the long-term effect of AL treatment during childhood have examined the leukaemia-treatment-related factors that have a role in the FH outcome (HSCT, TBI, CI), little is known about the efficacy or adverse effects of GH replacement therapy in these children. In this study, data on 25 patients with AL, who had HSCT/TBI or CI, and who had reached their FHs, were analysed. An overall decrease of À1.94 in FH Z-score value was found from AL diagnosis to FH. The height loss in our patients was comparable to that reported in the few studies published to date and reporting FH after GH treatment. 1, 2, 6, 7, 23 Height loss before start of GH treatment A decrease in the rate of growth in children after HSCT/ TBI or CI seems to be the result of an interaction of different factors related to the effects of chemotherapy, irradiation and steroid therapy (for example, damage to the epiphyseal growth plate) as well as multiple endocrinological causes (GHD, delayed or early puberty and hypothyroidism).
Before the onset of GH therapy, a significant decrease in height Z-score (À2.19) was observed in our study, slightly more than reported in previous studies, where s.d.s. ranged from À1.2 to À2 1, 2, 16, 17, 23, 24 (Table 3 ). In our study height loss from AL diagnosis to GHD diagnosis was greater in girls and in patients younger than 5 years at the time of cranial irradiation. This is in line with other data indicating that girls 17, 23 and younger patients 1,7 lose more s.d.s./Z before the start of GH treatment. Conversely, in the study of Sanders et al., 1 boys were shorter than girls at the last evaluation before GH therapy.
Response to GH treatment
Only few data are available on the response to substitution GH therapy on growth in heavily treated children with AL (Table 3 ). There are two types of studies: (1) those comparing height in treated vs untreated groups of patients and (2) those seeking factors affecting response to GH substitution in treated patients.
Besides problems linked to the fact that these are all retrospective, nonrandomised and small-series studies, two major difficulties arise in discussing these earlier findings. First, GHD diagnostic criteria differ among studies and not all the treated patients had biochemically proven GHD Second, the changes in height are more often evaluated from the therapeutic key points (HSCT or TBI or CI) to FH rather than from start of GH treatment to FH. When no information is available on the changes in height after start of GH therapy no valid conclusions can be drawn regarding the effect of GH therapy.
GH was generally administered at 20-30 mg/kg/day (0.4-0.7 IU/kg/week). Treatment duration was 3-4 years in most studies 6, 7, 15, 16 with 44 years 17, 23 or o1 year 25 of GH substitution in some others. Treatment duration was found to be a predictive factor for height loss in the study of Frisk et al. 7 In our study in which GH substitution was stopped when growth velocity was o1 cm/year (it was assumed that there would be no further benefit from continuing the treatment in these patients), there seemed to be a trend towards better height growth in children treated for longer than 2 years. The response to GH treatment varies. In our study there was an 'on-treatment' increase in height in 68% vs 85% of patients in the study of Bakker et al 15 (during the first year of treatment).
Like ours, most studies on the effect of GH therapy after AL treatment have shown an increase in growth rate after GH treatment was started compared with the pre-GH-treatment rate. Observed growth recovery rates during GH treatment were comparable in our study to that in Frisk et al. 7 ( þ 0.12 Z and þ 0.18 s.d.s./year) and estimated to be greater in Bakker et al. 15 ( þ 0.35 s.d.s. in the first year of treatment). Generally three scenarios are observed in patients with replacement GH therapy: (1) significant catch-up growth, for example, up to þ 1.2 s.d.s. in Leung et al. 17 and þ 0.59Z in our study; (2) a maintained height s.d.s./Z-score 15, 16, 23 and (3) 'only' a height s.d.s./Z-score loss reduction. 1, 2, 24 In our study, the overall recovery effect from start of GH therapy to FH was stronger in girls. The similar pattern of recovery was observed by Dai 23 in a small series of seven patients. This observation is also in agreement with Sanders and Cohen, who showed that girls had a better height growth from GHD diagnosis to FH than boys. 1, 6 Conversely, for Frisk et al. 7 there was no significant difference in height loss after BMT between boys and girls. The differences in height growth between girls and boys are not readily explained, suggesting that the reliability of this finding should be verified in specific studies.
An interaction of the GH treatment effect with age is expected. A significant interaction of the GH treatment effect with age at HSCT was observed by Sanders et al.
1
GH treatment resulted in 0.86 s.d. increase in FH in children with HSCT before the age of 10 years, whereas no significant effect of GH therapy was found in children receiving HSCT after the age of 10 years.
In our study we failed to confirm this. However, it should be emphasised that patient age at GH treatment is directly linked to patient age at AL treatment. The younger patients are at the time of AL treatment (growth failure), the younger they can be expected to be at the time of GH treatment (growth recovery). Therefore, younger patients are at greater risk of growth damage, but can also be expected to show better response to GH therapy and gain an additional s.d. or Z-score. This height gain could offset height loss so that the younger children who received GH would have a relative FH similar to the older children. Nevertheless, neither we could not act on patient age at diagnosis nor on the damage made by AL treatment, the point is not to lose time at initiation of GH treatment. In future studies, with a larger cohort of patients (continuing LEA programme ) and more detailed information of stage of puberty we may be able to define more precisely the subset of 'older' patients for whom GH substitution is still of great benefit.
FH
Data on FH achieved after HSCT/TBI/CI in response to GH therapy are very limited. In our study the median FH 17 (47 patients) after a median of 4.5 years of GH therapy there was a significant catch-up growth of about þ 1 s.d., resulting in adult heights in the normal range for most of the patients.
Four studies have reported on the impact of GH treatment on FH by comparing patients who had received GH and those who had not. In the first study by Cohen et al. 6 FH in 28 patients treated with GH was not statistically different from that of the remaining 153 untreated patients. Also, 77% of patients (treated and untreated) who attained their FHs reached normal heights. In the second study by Frisk et al., 7 although at FH there was no significant difference in height loss between those who had received GH (10 patients) and those who had not (6 patients), the authors support the use of early GH treatment in children with decelerating growth rate and low GH levels. In the third study by Sanders et al.,
1 GH-treated patients (42 patients) lost 0.06 s.d., whereas untreated ones (48 patients) lost 0.53 s.d. from GHD diagnosis to FH. In a fourth study by Chemaitilly et al. 16 the change in height for individuals treated with GH (seven patients) was less impaired than that observed in those not treated (five patients).
Toxicity of GH treatment
Overall incidence of second malignancies in LEA cohort was 3.6 and 8.9% in LEA HSCT patients. It should be noted that all patients who entered this long-term follow-up programme benefited from better screening and reporting than those who did not. In our study, 7 of 25 patients (28%) developed a second malignancy during or after the GH treatment had been discontinued. As in other studies we found that of these, papillary thyroid carcinoma was one of the most common. (Table 2) Published data from a Childhood Cancer Survivors Study cohort show that patients treated with GH had a threefold increased risk of developing a second neoplasm compared with untreated survivors. 26, 27 Among 361 survivors of childhood cancer who had GH treatment, 15 had second malignancies (4.1%). In the 119 AL survivors treated with GH, 4 developed a second solid neoplasm (3.4%): 2 osteosarcoma, 1 astrocytoma and 1 glioma. No case of secondary leukemia was described. 27 In the study of Sanders et al, 1 6/42 GH-treated patients (14%) developed a second neoplasm, 4 during and 2 after the completion of GH therapy. In the non-GH-treated group the incidence of secondary malignancy was 16.6% (8/48 patients). The types of malignancies observed were similar to those recorded after childhood transplantation. There was no significantly higher incidence of second neoplasm in a treated vs untreated group.
In 43 children with AL diagnosis and GH treatment Leung et al. 17 described two patients who developed a secondary malignancy (a sclerosing sweat duct carcinoma of the scalp and a myelodysplastic syndrome). There was no statistical evidence in this study that GH replacement therapy was associated with increased risk of secondary malignancy. In our study the number of patients with second malignancies was slightly higher than in the other studies. However, it should be compared with the incidence of second malignancies in non-GH treated patients from the LEA cohort. As we have not performed a matched controlled study on our cohort, we can only speculate that this might be explained by a relatively long period of follow-up (cumulative incidence increases with time) and/or AL-related-treatment intensity. Also, 25 patients with GHD described here are those who had the 'most aggressive' antileukaemia treatment (TBI, HSCT, GVH treatment). Therefore, GH treatment is not the only factor that impacts on the higher incidence of second malignancies in these patients.
Evidently, both these data and ours indicate a need for continued surveillance of childhood cancer survivors treated with GH.
Conclusion
These retrospective results are based on a small heterogeneous sample and therefore should be interpreted with caution. We found a measurable beneficial effect of GH treatment on growth up to FH, a finding already reported. As catch-up growth was observed in our patients we consider that a timely start of appropriate hormonal replacement therapy could help to reduce the negative impact of the AL-related treatment on the growth of paediatric patients. Therefore, in conclusion to this study, we propose that all children who are high-risk patients (HSCT, TBI, CI) should routinely undergo once a year testing of GH secretion in response to pharmacological stimuli and endocrine function. Figure 3 Algorithm proposed for a growth follow-up management in children after intensive AL treatment in the context of a future larger, randomized and long-term study. In this algorithm the choice between treatment and watchful waiting will be determined by based on clinical (growth velocity) and biological parameters (GH status but also endocrine function). Patients will be screened for GHD once a year. Those with biochemically proven GHD will be treated. Those without biochemically proven GHD and normal growth rate will be re-tested next year. Those without biochemically proven GHD and decreased growth rate (X2 s.d./ year) could be randomized for treatment or waiting group.
Moreover, in the context of a future larger, randomized, long-term study, the approach adopted could be to annually screen patients for GHD. Those with biochemically proven GHD will be treated. Those without biochemically proven GHD and normal growth rate will be retested next year. Those without biochemically proven GHD and decreased growth rate (X2 s.d./year) could be randomized for treatment or waiting group. Endocrine function should be taken into account (Figure 3) .
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